Search Results

Most Favored Nation RESOURCES > MOST FAVORED NATION Most Favored Nation Policymakers continue to explore “Most Favored Nation” policies in a stated attempt to lower the cost of medicines. Unfortunately, these efforts do nothing to actually reduce costs for the millions of patients who rely on medicines to manage chronic diseases. Broader consideration of the consequences of these types of policies on patient access and innovation, as well as a more realistic focus on the real drivers of cost in the system, such as insurance practices and pharmacy benefit managers, must remain a priority. The QALY Paradox: An Unintended Consequence Of Most Favored Nation Drug Pricing By Dominique Seo, Kenneth E. Thorpe, T. Joseph Mattingly II February 18, 2026 "What They Are Saying" Leading voices from patient, provider, and other stakeholder communities are raising serious concerns about the impact of the “Most Favored Nation” pricing proposal on patient access in America. PBM Reform, Not MFN Why PBM Reform, not MFN, is a Viable Path to Affordable Drug Access Chronic Voices, Critical Choices YouTube Series To shed some light on concerns about the Most Favored Nation proposal and its impact on people living with chronic conditions, the Partnership to Fight Chronic Disease (PFCD) is hosting short discussions with health and policy experts to address challenges to patient access, discriminatory value metrics like the QALY, and threats to future innovation. PFCD's Vice President of Policy Candace DeMatteis and Alliance for Aging Research's Director of Public Policy and Government Relations Adina Lasser examine the “Most Favored Nation” drug pricing proposal and what it could mean for older Americans who rely on Medicare. They discuss the flaws of the quality-adjusted life year (QALY) and explore better policy solutions to lower drug costs without undermining innovation, access, or long-term health outcomes. PFCD's Vice President of Policy Candace DeMatteis and Global Colon Cancer Association CEO Andrew Spiegel dive into the real-world consequences of the federal government’s proposed “Most Favored Nation” (MFN) drug pricing model for cancer patients. They explore how importing foreign price controls could restrict access to cutting-edge treatments, slow innovation, and jeopardize the U.S. leadership in cancer research. In this conversation, PFCD ’s Ken Thorpe and Caregiver Action Network CEO Marvell Adams examine how “Most Favored Nation” drug pricing could reshape access to medicines for Medicaid beneficiaries. They discuss the potential ripple effects on caregivers, including added burdens from restricted access or disrupted care, and consider the broader equity implications for vulnerable populations. The discussion also explores practical policy alternatives that protect affordability while preserving innovation and reliable access to lifesaving treatments. Hear what National Organization for Rare Diseases CEO Pam Gavin has to say about the impacts of adopting "Most Favored Nation" and foreign reference pricing on people's access to lifesaving therapies for rare disease. Listen to what former Congressman Larry Bucshon, MD thinks as he sheds light on concerns about the proposal and its impact on people living with chronic conditions, particularly related to patient access, discriminatory value metrics like the QALY, and threats to future innovation. PFCD Statements and Comment Letters December 19, 2025 The Partnership to Fight Chronic Disease (PFCD) released the following statement in response to the Centers for Medicare and Medicaid Services (CMS) announcement of mandatory demonstration projects that would implement Most Favored Nation (MFN) drug pricing in Medicare Parts B and D. August 1, 2025 The Partnership to Fight Chronic Disease (PFCD) issued the following statement in response to President Trump’s most recent efforts to impose “Most Favored Nation” (MFN) drug pricing, which poses considerable risks to patient access, particularly to people living with one or more chronic diseases. May 12, 2025 The Partnership to Fight Chronic Disease (PFCD) issued the following statement in strong opposition to President Donald Trump’s "Most Favored Nation" (MFN) executive order, which aims to tie prescription drug prices in the U.S. to those in foreign countries May 5, 2025 The Partnership to Fight Chronic Disease (PFCD) today called on Congressional leaders and the Trump Administration to ensure that treatment access for people living with chronic diseases in Medicaid remains a priority across new policies that aim to make America healthy now and in the future.

The Partnership to Fight Chronic Disease (PFCD) is an internationally-recognized organization of patients, providers, community organizations, business and labor groups, and health policy experts committed to raising awareness of the number one cause of death, disability, and rising health care costs: chronic disease Chronic Disease Patients Prioritized in Trump Administration Executive Order Since 2007, the Partnership to Fight Chronic Disease (PFCD) has been an internationally-recognized organization of patients, providers, community organizations, business and labor groups, and health policy experts committed to raising awareness of the number one cause of death, disability, and rising health care costs: chronic disease. The Problem: Preventable and Mismanaged Chronic Disease Chronic diseases, such as diabetes, COPD, cancer, depression, obesity and heart disease, are the leading causes of death and disability in the United States and account for the vast majority of health care spending. More than one in two American adults lives with at least one chronic condition and nearly one in three live with two or more chronic conditions. Chronic diseases are also the primary driver of health care costs—accounting for 90 cents of every dollar we spend on health care in this country. In 2011, this amounted to $2.3 trillion of the $2.7 trillion spent on health care. Despite these widespread problems, the issue of chronic disease does not register with large segments of the public and policymakers as an issue of primary concern. The Solution: A National Partnership Aimed at Fighting Chronic Disease As the CDC has said, “The United States cannot effectively address escalating health care costs without addressing the problem of chronic diseases.” Added to that, the World Health Organization estimates that as much as 80 percent of premature heart disease, stroke, and type 2 diabetes, and 40 percent of cancers could be avoided entirely if Americans avoided tobacco, developed healthier eating habits, and were more physically active. That’s why a broad group of patient, provider, community, business and labor groups, and health policy experts, joined together to form the Partnership to Fight Chronic Disease (PFCD)—a coalition committed to raising awareness of the rising rates of preventable and treatable chronic diseases. Our Mission: Rising rates of chronic diseases pose an unsustainable burden on our health care system. The viability and strength of the system—now and in the future—rely on a willingness to enact policies that help Americans better prevent and manage chronic illnesses. As a result, the mission of the PFCD is to: Drive awareness of burden of chronic disease and solutions at work shown to improve health for individuals and communities Empower change in how we prevent and treat chronic disease in America to enhance health Challenge decision-makers to adopt policy changes necessary to prevent and lessen burden of chronic disease

The Partnership to Fight Chronic Disease (PFCD) is an internationally-recognized organization of patients, providers, community organizations, business and labor groups, and health policy experts committed to raising awareness of the number one cause of death, disability, and rising health care costs: chronic disease Privacy Policy Last Updated: February 6, 2026 Your privacy is important to us at Partnership to Fight Chronic Disease (collectively “PFCD,” “we,” “us,” or “our”), and we are committed to safeguarding, preserving, and respecting your privacy rights. This online privacy Policy (the “Policy”) describes how we collect, use, disclose, and secure the personal information we gather about you through our website, https://www.fightchronicdisease.org (the “Site”), when you use our sites, apps, and when you otherwise interact with us (collectively, the “Services”). For purposes of this Policy, personal information means data that classifies as personal information, personal data, personally identifiable information, or similar terms under applicable data privacy and security laws and regulations. It does not include data excluded or exempted from those laws and regulations, such as aggregated, anonymized, or deidentified data. Nothing in this Policy will constitute an admission or evidence that any particular data privacy or information security law or regulation applies to PFCD generally or in any specific context. In providing our Services, PFCD may collect personal information on behalf and as a service provider for third parties. This Policy does not govern any information we collect on behalf of third parties, and you should consult their privacy policies to become familiar with their data collection and usage practices. You agree to receive recurring automated informational text (e.g., SMS and MMS) messages from Partnership to Fight Chronic Disease, including text messages that may be sent using an automatic telephone dialing system, to the mobile telephone number you provided when signing up or any other number that you designate. All the different types of messages you may receive (Informational messages, vote reminders, shall be known collectively as the "Programs." Consent to receive automated informational text messages is not a condition of any purchase. PFCD maintains strict privacy policies, ensuring that personal information of our users and members is not sold, rented, released, or traded to others without prior consent or a legal obligation. Personal information includes name, email address, phone number, and other contact information. SMS Opt-Out: If you are receiving text messages from us and wish to stop receiving them, simply respond with “STOP” to the number from which you received the message. Once we receive your message, you will no longer receive further text messages from us. 1. Cost Msg & Data rates may apply. Please consult with your carrier for rate information. 2. Message Frequency Message frequency will vary. We reserve the right to alter the frequency of messages sent at any time, so as to increase or decrease the total number of sent messages. We also reserve the right to change the phone number from which messages are sent. Not all mobile devices or handsets may be supported and our messages may not be deliverable in all areas. Our service providers and the mobile carriers supported by the program are not liable for delayed or undelivered messages. 3. Cancellation If you do not wish to continue participating in any Program or no longer agree to these Terms, you agree to text the applicable Short Code (or regular long code phone number where applicable) or directly reply to any mobile message received from a Program with STOP, END, CANCEL, UNSUBSCRIBE, or QUIT in order to opt out of that Program at any time. You may receive an additional mobile message confirming your decision to opt out. You understand and agree that the foregoing options are the only reasonable and exclusive methods of opting out. You also understand and agree that any other method of opting out, including, but not limited to, texting words or phrases other than those set forth above or verbally requesting to be removed from our list, is not a reasonable means of opting out. You may be subscribed to multiple Programs across different Short Codes or regular long code phone numbers, and therefore you must separately text or reply STOP to each Short Code or long code phone number from which you wish to unsubscribe. 4. Support For support regarding the Program, text “HELP” to the applicable Program’s Short Code or long code or email us at info@fightchronicdisease.org . Please note that the use of this email address, or texting “HELP” to the Program’s Short or long Code is not an acceptable method of opting out of the program. Opt-outs must be submitted in accordance with the procedures set forth above. Our Disclaimer of Warranty The Programs are offered on an "as-is" basis and may not be available in all areas at all times and may not continue to work in the event of product, software, coverage or other changes made by your wireless carrier. We will not be liable for any delays or failures in the receipt of any mobile messages connected with any Program. Delivery of mobile messages is subject to effective transmission from your wireless service provider/network operator, and is outside of our control. We are not liable for delayed or undelivered mobile messages. 5. Privacy Policy We respect your privacy. We will only use information you provide to transmit your mobile messages and respond to you, if necessary. This includes sharing information with our program partners, message content providers, phone companies, and vendors who assist us in the delivery of mobile messages. EXCEPT AS SET FORTH IN THIS SECTION, WE DO NOT SELL, RENT, LOAN, TRADE, LEASE OR OTHERWISE TRANSFER FOR PROFIT ANY PHONE NUMBERS OR CUSTOMER INFORMATION COLLECTED THROUGH PROGRAMS TO ANY THIRD PARTY. No mobile information will be shared with third parties/affiliates for marketing/promotional purposes. All the above categories exclude text messaging originator opt-in data and consent; this information will not be shared with any third parties. Nonetheless, we reserve the right at all times to disclose any information as necessary to satisfy any law, regulation or governmental request, to avoid liability, or to protect our rights or property. When you complete forms online or otherwise provide us information in connection with a Program, you agree to provide accurate, complete, and true information. You agree not to use a false or misleading name or a name that you are not authorized to use. If in our sole discretion, we believe that any such information is untrue, inaccurate, or incomplete, or you have opted into a Program for an ulterior purpose, we may refuse you access to the Program and pursue any appropriate legal remedies. This Privacy Policy and Terms and Conditions is strictly limited to these texting Programs and has no effect on any other privacy policy(ies) that may govern the relationship between you and us in other contexts. 6. You Consent to This Policy You should read this Policy carefully, so that you understand our privacy practices and our Terms of Use. By accessing, browsing, downloading, or otherwise using the Services, you confirm that you have read, understood, and agreed with this Policy. If you do not agree to this Policy, you may not use the Services. This Policy and the Terms of Use apply regardless of how the Services are accessed and will cover any technologies or devices by which we make the Services available to you. We may provide you with additional privacy notices where we believe it is appropriate to do so. It is important that you read this Policy together with any other privacy notice or terms we may provide on specific occasions, so that you are fully aware of how and why we are using your data. This Policy supplements these other notices and is not intended to override them. If you have any questions or concerns about our personal information policies or practices, you can contact us in the methods described in the “Contact Us” section below. 7. Types of Information We Collect We collect information you voluntarily provide directly to us, information that we collect automatically when you interact with the Services, and information collected from third parties. The categories of personal information that we collect and the purposes for which we collect that information are described below. (a) Categories of Personal Information We Collect The following list describes the categories of personal information we collect. Text Message Opt-In Information includes your opt-in consent to receive marketing messages from us through short codes or similar means. We collect this information for providing the Services, marketing and advertising our products and services, and for administrative purposes. Analytics Information. We collect certain analytics information automatically as you navigate our Services. This includes cookies, tracking pixels, tags or similar tools, which may collect information about your browser, device, geolocation, and interactions with the Services, Site, or emails. For more information, please view the “How We Use “Cookies” and Other Tracking Technologies” section below. We collect this information for the purposes of account creation and management, advertising and marketing, analytics and research, customer service, and website security and maintenance. Contact Information includes name, zip code, email address, and phone number. We collect this information when you provide it directly to us, through publicly available sources, or from other public action committees or political organizations. Petition, Campaign, and Voting Information means information relating to you engagement with us, petitions, or campaigns, as well as public voter data. We collect this information from publicly available sources, or from other political action committees or political organizations. Social Media Information includes information that you post by sharing on a blog or another social media platform. We collect this information when you provide it directly to us. Please note that your comments will be visible to the public, so you should never share personal information that you would like to keep private User-Generated Content. If you post, upload, comment, or otherwise submit content on the Services, we may collect certain information about you such as your name and email address and products you may have purchased. Be aware that as a default, any information you post on the Services, including without limitation reviews, comments, and text, may be available to and searchable by all users of the Services. We collect this information for the purposes of account creation and management, advertising and marketing, analytics and research, customer service, and website security and maintenance. (b) How We May Collect, Use, or Share the Information We may also reserve the right to collect, use, or share personal information for the following purposes: To Provide the Services. We will use your personal information to provide the Services, including to improve operations and offerings, and for security purposes. To Present the Site. We will use personal information to present our Site and its contents in a suitable and effective manner for you and your device. Election and Political Activities. We may use your personal information in connection with our election and political activities, including advertising efforts. For Legal Purposes. We reserve the right to cooperate with local, provincial, state, federal and international officials in any investigation requiring either personal information or reports about lawful or unlawful user activity on this site. We also reserve the right to share your personal information to establish, exercise, or defend our legal and property rights, including providing information to others for the purposes of fraud prevention. We may also share your personal information with any person who we reasonably believe may apply to a court or other competent authority for disclosure of that personal information where, in our reasonable opinion, such court or authority would be reasonably likely to order disclosure of that personal information. If we are ordered by a legal process or government to provide data about one or more individual users, we will notify those users of our compliance with that order, to the extent permitted by law. Business Partners and Affiliates. We may collect personal information from and share personal information with our business partners and affiliates, including legal advisors and financial advisors, co-branded partners, and other third parties. We may combine that information with other information we collect about you, but we will always use the information as described in this Policy. We may also share information with our affiliates, subsidiaries, joint ventures or other companies under common control. Business Transactions or Mergers. We reserve the right to share your personal information to third parties as part of any potential business or asset sale, merger, acquisition, investment, round of funding, or similar type of transaction. Additionally, if we are entering into a corporate transaction with a third party, we may receive personal information in connection with the diligence. If we close a transaction, the third party may transfer personal information, which we would use as described in this Policy. Bankruptcy or Insolvency. In the event of bankruptcy, insolvency, or dissolution proceedings, we may share your personal information with third parties as part of the sale or reorganization process. Provide Information and Opportunities. We will use your personal information to advertise travel opportunities, promotions, products, events, or Services that we think may be of interest to you. Service Providers. We use service providers to perform various functions on our behalf, including background screening service providers. Such service providers will be under contractual obligations to safeguard your personal information and only process it in accordance with our instructions, or as otherwise permitted by applicable laws. We may also receive personal information from service providers. 8. How We Use “Cookies” and Other Tracking Technologies We may send one or more cookies to your computer or other device. We may also use other similar technologies such as tracking pixels, tags, or similar tools when you visit our Services. These technologies can collect data regarding your operating system, browser type, device type, screen resolution, IP address, and other technical information, as well as navigation events and session information as you interact with our Services. This information allows us to understand how you use the Services. (a) Cookies Cookies are small files created by websites, including our Services, that reside on your computer’s hard drive and that store information about your use of a particular website. When you access our Services, we use cookies and other tracking technologies to: Estimate our audience size and usage patterns; Store information about your preferences, allowing us to customize our Services according to your individual needs; Contact you to provide you with information or services that you request from us; Advertise new content, events, and services that relate to your interests; Provide you with more personalized content that is most relevant to your interest areas; and Recognize when you return to our Services. We set some cookies ourselves and others are set by third parties. You can manage your cookies preference as described in the “Managing Your Cookies” section below. The following chart lists the different types of cookies that we and our service providers use on the Services, examples of who serves those cookies and links to the privacy notices and opt-out information of those cookie servers. Because the specific cookies we use may vary over time, as well as differ by the specific page you are browsing, the below chart is illustrative only. Types of Cookies Purpose Who Serves (for example) Analytics, Performance, and Research These cookies, beacons, and pixels allow us to analyze activities on the Services. They can be used to improve the functioning of the Services. For example, these cookies recognize and count the number of visitors and see how they move around the Services. Analytics cookies also help us measure the performance of our advertising campaigns to help us improve them and to optimize the content on the Services for those who engage with our advertising. Cloudfare Essential These cookies are required for the operation of the Services and enable you to move around the Services and use its features. Disabling these cookies can negatively impact the performance of Services. Wix Advertising These cookies and pixels are used to deliver relevant ads, track ad campaign performance, or track email marketing. N/A Social Networking These cookies are used to enable you to share pages and content that you find interesting on our Services through third-party social networking and other websites. These cookies may also be used for advertising purposes. LinkedIn Meta X Functionality These cookies are used to recognize you when you return to the Services. This enables us to personalize content for you and remember your preferences. These cookies also enable your interactions with the Services such as emailing us and customer support chat. Wix We do not use analytical tools in a manner that discloses to third parties that a specific person viewed specific video materials. (c) Cookie Retention Period Some cookies operate from the time you visit the Services until the end of that particular browsing session. These cookies, which are called “session cookies,” expire and are automatically deleted when you close your Internet browser. Some cookies will stay on your device between browsing sessions and will not expire or automatically delete when you close your Internet browser. These cookies are called “persistent cookies” and the length of time they will remain on your device will vary from cookie to cookie. Persistent cookies are used for a number of purposes, such as storing your preferences so that they are available for your next visit and to keep a more accurate account of how often you visit the Services, how your use of the Services may change over time, and the effectiveness of advertising efforts. (d) Managing Your Cookies It may be possible to block cookies by changing your Internet browser settings to refuse all or some cookies. If you choose to block all cookies (including essential cookies), you may not be able to access all or parts of the Services. You can find out more about cookies and how to manage them by visiting https://ico.org.uk/for-the-public/online/cookies/ . (e) Site Response to “Do Not Track” Signals At this time, our Site does not respond differently based on a user’s Do Not Track signal. 9. Advertising and Marketing Choices We respect your rights in how your personal information is used and shared. We may communicate with you via email, telephone, postal mail, and/or your mobile device about our products and services. If at any time you would like to unsubscribe from receiving future marketing emails, you can email us at info@fightchronicdisease.org or follow the instructions at the bottom of each applicable email, and we will promptly remove you from those marketing correspondences that you choose to no longer receive. Please note, however, that we may still need to contact you regarding other matters. 10. How Long Your Personal Information Is Kept We will retain your personal information until the personal information is no longer necessary to accomplish the purpose for which it was provided. We may retain your personal information for longer periods for specific purposes to the extent that we are obliged to do so in accordance with applicable laws and regulations, to protect you, other people, and us from fraud, abuse, an unauthorized access, as necessary to protect our legal rights, or for certain business requirements. We will delete your personal information when it is no longer necessary for the purpose for which it was collected, or upon your request, subject to exceptions as discussed in this Policy or under applicable law, contract, or regulation. 11. Our Commitment to Data Security The security of your personal information is important to us. We take various reasonable organizational, administrative, and technical measures to protect your personal information from unauthorized access, disclosure, alteration, or destruction. If required by law to do so, we will notify you and/or the relevant supervisory authority in the event of a data breach. However, we cannot and do not guarantee complete security, as it does not exist on the Internet. 12. Where Your Personal Information Is Held We process personal information on our servers in the United States of America, and may do so in other countries. If you use our Services or otherwise provide us with information from outside of the United States, you expressly consent to the transfer of your data to the United States, the processing of your data in the United States, and the storage of your data in the United States. 13. Third Party Links Our Services may contain links to third-party websites. When we provide links, we do so only as a convenience and we are not responsible for any content of any third-party website or any links contained within. It is important to note that this Policy only applies to our Services. We are not responsible and assume no responsibility for any personal information collected, stored, or used by any third party as a result of you visiting third-party websites. We also advise that you carefully read the privacy notice of any third-party websites you choose to visit. 14. Children’s Privacy Protecting the privacy of the very young is especially important. Our Services are not intended for children under 13 years of age, and we do not knowingly collect personal information from children under 13. In the event that we learn that we have collected personal information from a child under age 13 without verification or parental consent, we will immediately delete that information. If you believe that we might have any information from or about a child under 13, please contact us using the information provided in the “Contact Us” section below. 15. Policy Changes This Policy may change from time to time. If we need to change this Policy at some point in the future, we will post any changes on this page. If we make a significant or material change to this Policy we will notify you via email. You should check these terms when you use the Site. Your continued use of the Services constitutes acceptance of the most current version of this Policy. 16. Contact Us If you have any questions about this Privacy Policy, please contact us by email at info@fightchronicdisease.org .

Patients lose access to lifesaving therapies when governments impose drug price controls, and the consequences are measured in delayed treatment, depleted research pipelines and lives cut short, according to a new research analysis from the Information Technology and Innovation Foundation (ITIF). ITIF examined how European drug pricing policies drove the continent's fall from global biopharmaceutical leadership. While compiling and assessing existing research on the patient impact, the independent think tank called Europe a "cautionary tale" for the U.S., particularly as the Trump administration continues to champion the expansion of price controls through “Most Favored Nation” (MFN) drug pricing policies. Patient wait times for treatment availability, as measured from regulatory approval to payer coverage, were slower in 25 of the 27 EU nations compared to the U.S. from 2014 to 2022, according to IQVIA. The Galen Institute found that, of 290 new medicines introduced globally between 2011 and 2018, 89% were available in the U.S. compared with only 62% in Germany, 48% in France and Switzerland, and 40% in Ireland. The data were starker for oncology medicines: 96% were available to American patients compared with 73% in Germany, 66% in France, 62% in Switzerland and 51% in Ireland. The report also traced the erosion of the pipelines that deliver patients new therapies. Between 1960 and 1965, European firms produced 65% of all new medicines worldwide. By 2004, that share collapsed to 18% while the U.S. share climbed to 62%. ITIF cited research by University of Southern California health economist Darius Lakdawalla and his colleagues, who found that lowering U.S. drug prices to European levels would reduce life expectancy for adults ages 55 to 59 by roughly two-tenths of a year. That amounts to more than four million life-years lost across that age group alone. For the more than 194 million Americans living with multiple chronic conditions, the analysis of Europe's decline hits close to home. These patients depend on a steady flow of new therapies to manage illness, preserve quality of life and survive. As a recent Partnership to Fight Chronic Disease study explored, chronic conditions are the primary driver  of rising health care spending across Medicare, Medicaid and private insurance, and obesity is a primary culprit. Adding longer wait times for new treatments to an already strained U.S. health care system would delay care, worsen patient outcomes and drive costs higher. The risk is too great. Ultimately, ITIF's analysis is a patient story. Europe's experience shows what happens when governments suppress the returns that fuel innovation. Americans with chronic disease cannot afford for history to be repeated. The full report from ITIF can be found HERE .

February 25, 2026 (WASHINGTON, D.C.)  — The Partnership to Fight Chronic Disease (PFCD) released the following statement in response to the State of the Union address, during which President Trump supported codifying “Most Favored Nation” (MFN) drug pricing: “The 194 million Americans living with multiple chronic conditions depend on consistent, timely access to the therapies that help manage their health. Ensuring these treatments are affordable is a goal PFCD strongly supports, and one that President Trump rightly elevated in his State of the Union address. Codifying MFN into law, however, would fundamentally shift the U.S. toward access delays and gaps observed in the countries that MFN pricing would emulate without any guarantees of improving affordability for patients. “Americans living with complex, chronic conditions cannot afford the disruption and volatility MFN would bring to the U.S.-based innovation ecosystem, jeopardizing access to new therapies for cancer, autoimmune disorders, neurological conditions, and rare diseases. MFN would also import foreign benchmarks that rely on discriminatory cost-effectiveness measures like the quality-adjusted life year (QALY), a metric that systematically undervalues the lives of elderly, disabled and chronically ill patients , and that federal law explicitly prohibits in Medicare. Importing those prices means importing the discriminatory assumptions on which they are built. "The patients most dependent on a stable, innovative therapeutic landscape are also the most vulnerable to the consequences of getting this wrong. PFCD urges Congress to avoid codifying a policy that risks undermining both American values and biomedical innovation. To deliver on President Trump’s desire to improve health care affordability, Congress must instead focus its energy on the insurance companies that stand between patients and their medicines while continuing to drive up premiums, deductibles, and coinsurance. We stand ready to work with policymakers toward affordability solutions that keep patient access, outcomes and medical progress at the center." For more health and policy stakeholder perspectives on MFN, please visit www.fightchronicdisease.org/mfn .

February 4, 2026 (WASHINGTON, D.C.)  The Partnership to Fight Chronic Disease (PFCD) applauds the passage of the Consolidated Appropriations Act of 2026 and its inclusion of many important health care elements that support efforts to better prevent and manage costly chronic conditions. Notably, the bill will increase transparency and lower health care costs for people living with one or more chronic conditions by instituting much needed reforms for pharmacy benefit managers (PBMs) in both Medicare Part D and the commercial market. This represents an important first step toward holding PBMs accountable, protecting patient access, and improving the affordability of prescribed medications. More specifically, the PBM reforms included in this package would: Require Part D plans to contract with any pharmacy that meets reasonable, relevant standard terms, with HHS directed to define and enforce those standards beginning in 2029. Limit PBM compensation in Part D to flat, bona fide service fees, fully delinked from drug prices, formularies, and utilization, while passing through rebates and discounts. Mandate comprehensive PBM reporting in Part D on drug utilization, pricing, rebates, retained compensation, and PBM-owned pharmacy activity starting in 2028. Bar PBM contracts that restrict disclosure or reporting, ensuring access to financial and utilization data across the commercial market. Require regular, drug-level reporting to federal agencies on pricing, compensation, rebates, and benefit designs that steer patients to PBM-affiliated pharmacies for PBMs in the commercial market. Require PBMs serving ERISA plans to pass through 100% of rebates and related payments to the issuer, grant audit rights, and strengthen fee and rebate disclosure. The new law also enables better prevention and early detection of cancer by allowing Medicare to cover cutting-edge multi-cancer diagnostics that can detect multiple cancers from a single blood test. Other important provisions in this legislation that aim to advance the fight against chronic disease focus on improving access to care across Medicare and rural communities, funding research for cancer and Alzheimer’s and supporting mental health services. PFCD stands ready to engage with the Administration as relevant agencies work to implement this legislation. We call upon Congress to continue to pursue bipartisan, patient-centered reforms to PBM and health plan behaviors that inhibit access and affordability for the millions of U.S. individuals and families managing chronic conditions.